LIMS Selection is no small task. A laboratory information management system (LIMS) represents a central hub for managing many of the operations in the modern laboratory. Originally, LIMS were designed to be a simple sample tracking tool, enabling systematic control of workflows in regulated environments. Recent years have seen the evolution of LIMS into more of an enterprise resource planning tool that can manage multiple aspects of laboratory informatics – resource management/scheduling, assay data management, data mining, data analysis, case-centric clinical data, and electronic laboratory notebook (ELN) integration.
The paper-based lab versus the digital lab. The largest barrier to innovation for any lab is performing tasks manually and recording experiment data in paper lab notebooks. Easy-to-use digital applications can increase productivity while reducing wasted time and inefficiencies associated with searching for relevant experiment data.
Analysts have estimated the failure rate of commercial laboratory information management systems (LIMS) to be as high as 60 percent with many of them failing to deliver original customer requirements after lengthy and expensive deployments.
This BIOVIA customer uniquely combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility associated with the world of biotech. The company focuses on a range of illnesses including cancer, cardiovascular disease, diabetes, hepatitis B, HIV/ AIDS, rheumatoid arthritis and psychiatric disorders. Their R&D organization prioritizes pipeline velocity and sales growth while continuing to manage costs.
One area coming under increased regulatory scrutiny is change control: the ability to manage deviations to established policies and procedures in a way that is efficient, timely and compliant.
Current market conditions such as regulations and mergers or acquisitions make improving compliance and manufacturing efficiency while driving to grow revenue and margins difficult. Read on to understand strategies, frameworks and recommendations to achieve these goals.
With biologics filling the pipelines of life sciences companies more than ever, the biopharmaceutical industry needs to rethink its view of quality. Once primarily considered a focus in downstream drug development and manufacturing, quality now demands just as much attention in upstream discovery research.
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM)